Hanall Biopharma (009420) — Cash Flow-to-Debt Ratio
Hanall Biopharma (009420) has a Cash Flow-to-Debt Ratio of 0.17x as of September 2025, meaning its operating cash flow of ₩7.34 Billion could theoretically repay 0% of its total liabilities (₩44.17 Billion) in one year. See 009420 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hanall Biopharma Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Hanall Biopharma across 14 annual periods. Also explore 009420 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Hanall Biopharma (2011–2024)
Year-by-year debt coverage analysis for Hanall Biopharma. For market capitalisation and broader financial context, see 009420 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.21x | ₩9.36 Billion | ₩44.53 Billion | ▼ -62.0% |
| 2023 | 0.55x | ₩29.64 Billion | ₩53.53 Billion | ▼ -0.7% |
| 2022 | 0.56x | ₩25.20 Billion | ₩45.19 Billion | ▲ +2223.1% |
| 2021 | 0.02x | ₩839.87 Million | ₩34.99 Billion | ▲ +0.4% |
| 2020 | 0.02x | ₩929.29 Million | ₩38.86 Billion | ▼ -94.1% |
| 2019 | 0.40x | ₩20.49 Billion | ₩50.97 Billion | ▲ +709.4% |
| 2018 | -0.07x | ₩-2.99 Billion | ₩45.39 Billion | ▼ -109.0% |
| 2017 | 0.73x | ₩42.14 Billion | ₩57.50 Billion | ▲ +278.0% |
| 2016 | 0.19x | ₩3.95 Billion | ₩20.37 Billion | ▲ +1035.7% |
| 2015 | -0.02x | ₩-454.02 Million | ₩21.91 Billion | ▲ +75.6% |
| 2014 | -0.09x | ₩-3.52 Billion | ₩41.36 Billion | ▲ +58.2% |
| 2013 | -0.20x | ₩-7.78 Billion | ₩38.23 Billion | ▼ -522.4% |
| 2012 | 0.05x | ₩2.20 Billion | ₩45.60 Billion | ▼ -64.4% |
| 2011 | 0.14x | ₩7.41 Billion | ₩54.75 Billion | — |